Ever since COVID-19 began its global spread, startups have been working on ways to provide more accurate, convenient, or lower-priced tests to detect the virus. Now that several have reached scale, they’re looking to take their offerings to the public markets.
Subscribe to the Crunchbase Daily
In the past week, two upstart test providers have advanced plans for share offerings. San Diego-based Cue Health, which develops and sells molecular at-home tests, is pursuing a traditional IPO, and Hong Kong-based Prenetics plans to go public through a merger with a blank-check acquirer.
The two are among more than a dozen …
Related posts:
The Week’s 10 Biggest Funding Rounds: Amazon Aggregator Thrasio, Productivity Software And Healthtec...
The Briefing: Udemy Slips In First Day On Nasdaq, Kurly Eyes Market Debut, And More
VC Dealmaking Has Reached a Crescendo, But This Isn’t 1999 All Over Again
The Briefing: CRED Picks Up $251M, Delivery Hero Backs Gorillas, And More
